Non-squamous, Non-small cell lung cancer
Conditions
Interventions
CBDCA AUC=5 (Day1) Paclitaxel 200mg/m2 (Day1) Bevacizumab 15mg/kg (Day0 or1) and Surgery
Sponsors
Osaka International Cancer Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically proven non-squamous non-small cell lung cancer 2) Patients with resectable stage IIIA (UICC-7th edition) 3) Without previously treatment for lung cancer 4) Age:20-74 5) PS:0-1 6) Expected FEV 1.0 > 1.0L after lung resection 7) Adequate organ function 8) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Active double cancer 2) Current history of hemoptysis 3) Evidence of bleeding diathesis or coagulopathy 4) With great vessel invasion 5) Cavity in tumor 6) History of uncontrollable pericardial effusion 7) History of severe heart disease 8) Current or previous history (within the last 1 year) of symptomatic cerebrovascular disease 9) Active infectious disease in need of intravenous administration of anti-bacterial, anti-fungal, or anti-viral drugs 10) Receiving anticoagulant drug (except Aspirin within 324 mg/day) 11) Uncontrollable Gastrointestinal ulceration 12) Current or previous(within the last 1 year)history of GI perforation 13) Uncontrollable systemic disease (hyper tension or diabetes mellitus) 14) Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 15) Peripheral neuropathy > Grade2 16) With a history of drug sensitivity 17) History of pregnancy or lactation 18) No intention to practice birth control 19) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of completion of the protocol treatment Overall survival Disease-free survival clinical and pathologic response Complete resection rate Toxicity Intraoperative and postoperative complications | — |
Countries
Japan
Contacts
Public ContactJiro Okami
Osaka International Cancer Institute General thoracic surgery
Outcome results
None listed